Chronic Pain Clinical Trials Programs Topical 
NORML
APRIL 30, 2020
The Centers for Disease Control and Prevention is seeking public comments on how Americans with chronic pain are successfully treating their symptoms. CDC invites comments specifically on topics focused on using or prescribing opioid pain medications, non-opioid medications, or non-pharmacological treatments.”
MMJ Recs
MAY 9, 2024
There are multiple US states with an established state-approved medical marijuana program as well as states permitting the use of cannabinol (CBD) oil – a non-psychoactive component of cannabis – for medical purposes exclusively.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MMJ Recs
APRIL 1, 2024
Studies have suggested that CBD may help manage chronic pain, reduce anxiety and depression, alleviate symptoms of epilepsy, and even aid in cancer treatment. From oils and tinctures to capsules and topical creams, CBD is available in various forms to suit individual preferences and needs.
Cannabis Law Report
MAY 10, 2022
The first in-depth study of Australia’s medicinal cannabis program, which began in 2016, shows the drug is being increasingly prescribed for various conditions. Since the beginning of the program, medicinal cannabis has been prescribed for over 140 conditions. The findings were published today in Frontiers in Pharmacology.
MMJ Recs
DECEMBER 22, 2023
Medical marijuana, once a controversial and stigmatized topic, has undergone a remarkable transformation in the eyes of the American public. Studies have shown the efficacy of medical cannabis in treating conditions such as chronic pain, epilepsy, and certain mental health disorders.
TheAnswerPage
JANUARY 11, 2022
As reviewed in a recent Forbes article, “a study of more than 400 health care professionals has revealed that most physicians lack knowledge of medicinal cannabis, with 65% saying that they have been asked about medical marijuana as a treatment for chronic pain but were unable to answer their patients’ questions” (1).
Cannabis Law Report
DECEMBER 20, 2021
(“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, signed a clinical trial agreement with Altasciences Company, Inc., Virpax is initially seeking FDA approval of its three patented drug delivery platforms.
Expert insights. Personalized for you.
332 
Let's personalize your content